

Esther Masih-Khan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5875112/publications.pdf>

Version: 2024-02-01

25
papers

213
citations

1478505

6
h-index

1058476

14
g-index

25
all docs

25
docs citations

25
times ranked

459
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 23-30. | 3.0 | 0 |
| 2 | Kinetics of response to first and second line therapies in multiple myeloma: Assessment by both M α spikes and light chains. <i>European Journal of Haematology</i> , 2022, 108, 204-211. | 2.2 | 0 |
| 3 | Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 826342. | 2.8 | 3 |
| 4 | Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 608-617. | 0.4 | 4 |
| 5 | Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database. <i>Current Oncology</i> , 2022, 29, 1575-1582. | 2.2 | 3 |
| 6 | Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database. <i>British Journal of Haematology</i> , 2022, 198, 93-102. | 2.5 | 3 |
| 7 | The impact of lenalidomide maintenance on second line chemotherapy in transplant eligible patients with multiple myeloma. <i>European Journal of Haematology</i> , 2021, 106, 673-681. | 2.2 | 2 |
| 8 | Real world outcomes with bortezomib containing regimens and lenalidomide plus dexamethasone for the treatment of transplant ineligible multiple myeloma: a multi institutional report from the Canadian Myeloma Research Group database. <i>British Journal of Haematology</i> , 2021, 193, 532-541. | 2.5 | 9 |
| 9 | Retrospective study of treatment patterns and outcomes post lenalidomide for multiple myeloma in Canada. <i>European Journal of Haematology</i> , 2021, 107, 416-427. | 2.2 | 4 |
| 10 | The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database. <i>Haematologica</i> , 2021, 106, 1733-1736. | 3.5 | 11 |
| 11 | Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1837-1837. | 1.4 | 1 |
| 12 | Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. <i>Blood</i> , 2021, 138, 4721-4721. | 1.4 | 0 |
| 13 | Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras. <i>Bone Marrow Transplantation</i> , 2020, 55, 578-585. | 2.4 | 17 |
| 14 | Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database. <i>Blood</i> , 2020, 136, 26-27. | 1.4 | 1 |
| 15 | Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. <i>Blood</i> , 2020, 136, 5-7. | 1.4 | 0 |
| 16 | Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma: A Retrospective Review of a Single-center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e195-e203. | 0.4 | 4 |
| 17 | Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?. <i>Blood</i> , 2019, 134, 5704-5704. | 1.4 | 0 |
| 18 | Real-World Outcomes with Bortezomib-Containing Regimens and Lenalidomide Plus Dexamethasone for the Treatment of Transplant Ineligible MM Patients: A Multi-Institutional Report from the National Myeloma Canada Research Network (MCRN) Database. <i>Blood</i> , 2018, 132, 2008-2008. | 1.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Secondary primary malignancies during the lenalidomide+dexamethasone regimen in relapsed/refractory multiple myeloma patients. <i>Cancer Medicine</i> , 2017, 6, 3-11. | 2.8 | 24 |
| 20 | Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 387-394. | 0.4 | 11 |
| 21 | Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting. <i>Blood</i> , 2016, 128, 2137-2137. | 1.4 | 3 |
| 22 | Addition of Cyclophosphamide, on Demand, to Lenalidomide and Corticosteroids in Patients with Relapsed/Refractory Multiple Myeloma, a Retrospective Review of a Single Centre Experience. <i>Blood</i> , 2015, 126, 1842-1842. | 1.4 | 0 |
| 23 | Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Induction Therapy For Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2013, 122, 3231-3231. | 1.4 | 3 |
| 24 | Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years. <i>Blood</i> , 2013, 122, 5315-5315. | 1.4 | 0 |
| 25 | Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 773-779. | 2.0 | 108 |